Skip to main navigation
Skip to search
Skip to main content
Research Explorer The University of Manchester Home
Home
Profiles
Research units
Research output
Projects
Impacts
Activities
Press/Media
Prizes
Equipment
Datasets
Student theses
Search by expertise, name or affiliation
Mairead Mcnamara, MB, BCh, BAO, B Med Sci, BSc, PhD, FRCP UK
Dr
Clinical Senior Lecturer/Hon Consultant
,
Division of Cancer Sciences (L5)
https://orcid.org/0000-0002-2272-3678
Overview
Fingerprint
Network
Research output
(270)
Projects
(4)
Impacts
(1)
Press/Media
(2)
Similar Profiles
(6)
Supervised Work
(2)
Research output
143
Article
67
Abstract
31
Poster
8
Review article
21
More
7
Letter
3
Conference contribution
3
Other
2
Chapter
2
Editorial
1
Book
1
Paper
1
Book/Film/Article review
1
Commentary/debate
Research output per year
Research output per year
3 results
Publication Year, Title
(descending)
Publication Year, Title
(ascending)
Title
Type
Filter
Other
Search results
2014
REDUCTION IN NEUTROPHIL-LYMPHOCYTE RATIO DURING INITIAL CONCURRENT CHEMORADIOTHERAPY IS PROGNOSTIC FOR SURVIVAL OF GLIOBLASTOMA PATIENTS
Mason, M.,
Mcnamara, M.
, Tieu, M., Lwin, Z., Millar, B., Menard, C., Laperriere, N., Milosevic, M., Mason, W. & Chung, C.,
Oct 2014
.
Research output
:
Contribution to conference
›
Other
Chemoradiotherapy
100%
Glioblastoma
100%
Neutrophil
100%
Lymphocyte
100%
Dexamethasone
100%
Temozolomide for 1p19q co-deleted and partially deleted gliomas
Mcnamara, M.
, Jiang, H., Fat, M. J. L., Sahebjam, S., Kiehl, T. R., Karamchandani, J., Coire, C., Chung, C., Millar, B.-A., Laperriere, N. & Mason, W. P.,
27 Sept 2014
.
Research output
:
Contribution to conference
›
Other
Oligodendroglioma
100%
Temozolomide
100%
Radiation Therapy
33%
Procarbazine
16%
Lomustine
16%
2012
Conditional probability of survival in patients with glioblastoma multiforme in the temozolomide treatment era.
Mcnamara, M.
, McNamara, M., Lwin, Z., Jiang, H., Chung, C., Millar, B., Laperriere, N. & Mason, W.,
2012
.
Research output
:
Contribution to conference
›
Other
Glioblastoma Multiforme
100%
Temozolomide
100%
Radiation Therapy
44%
Frontal Lobe
22%